Management of Graves Thyroidal and Extrathyroidal Disease: An Update

1This mini-review offers an update on the diagnosis and management of patients with thyroidal and extrathyroidal Graves disease (GD). The purpose is to avoid repeating known and general knowledge. Hence, this update emphasizes the recent developments, for example, the serological accurate and rapid diagnosis of GD as well as its worldwide acknowledged favored medical treatment. It reports on the insulin-like growth factor-1 receptor (IGF-1R) as novel autoantigen in GD and associated Graves orbitopathy (GO). Further, this short review introduces novel, more disease-specific treatments for both GD and GO with special focus on the recently FDA-approved IGF-1R inhibiting monoclonal antibody teprotumumab. Finally, the management of GD and GO in the time of the COVID-19 pandemic is discussed.

2The prevalence of GD approximates 1% to 1.5% in the population as a whole: the incidence is 20 to 30 new cases/100 000/year. An increased incidence is observed among African Americans. Both genetic and environment factors, for example, familial clustering, negative life experiences, high iodine intake, and smoking, predispose to GD. GD is a systemic autoimmune disease directly caused by circulating autoantibodies (Abs) that bind to the thyrotropin receptor (TSH-R), subsequently inducing the production and release of thyroid hormone, proliferation of thyrocytes, and enlargement of the thyroid gland. The stimulatory TSH-R-Ab (TSAb) is the causative agent in GD in patients suspected of having hyperthyroidism, with associated signs and symptoms. TSAb increases intracellular cyclic adenosine 5′-monophosphate directly when in contact with the TSH-R and can be detected in a bioassay using chemiluminescence. Further, TSAbs directly and specifically induce oxidative stress in GD.

3Pertinent and current guidelines, original articles, clinical trials, systemic reviews, and meta-analyses were searched by using the following terms: “diagnosis of Graves’ disease,” “imaging of Graves’ disease,” “management of Graves’ disease,” “treatment of autoimmune hyperthyroidism,” “autoimmune thyrotoxicosis,” antithyroid drugs, thionamides, radioactive iodine, thyroidectomy, “Graves’ orbitopathy and/or ophthalmopathy,” “thyroid eye disease,” and “extrathyroidal Graves’ manifestations.”

4The measurement of serum baseline TSH is the acknowledged screening parameter in the initial evaluation of suspected thyroid dysfunction. Additional assessment of the free thyroid hormones differentiates between overt and subclinical hyperthyroidism.

5TSH-R-Ab measurement offers accurate and fast diagnosis of GD (Fig. 1). The conventional TSH-R-Ab binding immunoassays are sensitive and specific (98 and 99%, respectively); however, these assays do not differentiate between Ab functionality. In comparison, the cell-based bioassays measure TSH-R-Ab concentrations at very low Ab concentration and at very high serum dilution, and exclusively report on TSH-R-Ab functionality. Indeed, the bioassays show the functionality of the TSH-R-Abs that interact with the human TSH-R, and can specifically detect TSAbs, differentiating between the TSH-R-Ab types (blocking/stimulating). Functional TSH-R-Abs are also predictive for extrathyroidal manifestations and for neonatal thyroid dysfunction. Further to their clinical utility and diagnostic relevance, measurement of stimulatory TSH-R-Abs markedly reduces both costs and time to diagnosis of GD by 50%.

6Thyroid ultrasound comprises conventional gray-scale analysis (using a high-frequency linear probe) and color flow Doppler examination (characterizing vascular patterns and quantifying thyroid vascularity). Ultrasound supports the diagnosis of GD as a noninvasive, rapid, and accurate imaging procedure. If a goiter with large nodules is present and/or if radioactive iodine (RAI) therapy is indicated, radionuclide scintigraphy with radioiodine uptake is suggested. In the vast majority of cases, a timely and positive TSH-R-Ab serology with a typical ultrasound finding offers a reliable, rapid, and more than sufficient definitive diagnosis of GD.

7Three equally potent approaches are offered to treat Graves hyperthyroidism: medical therapy by inhibiting production of thyroid hormones, complete surgical removal of the thyroid gland (total thyroidectomy), or RAI-induced shrinkage of the thyroid tissue (Fig. 1 and Table 1). The importance of patient choice, in a shared decision-making process, both at the initial episode of hyperthyroidism and at recurrence, should be emphasized.

8The thionamide antithyroid drugs (ATDs) have been the most common treatment of GD in Asia, Europe, and Latin America, in contrast to the USA where RAI has been more prevalent. More recently, however, ATDs have been used in nearly 60% of GD patients in the USA versus 35% only for RAI. This is mainly because RAI is associated with both sustained increases in TSH-R-Ab titers after RAI and a definite risk for a de novo GO and/or exacerbation of the clinical activity and severity of the orbital disease.

9The thiourea derivatives (ATDs) inhibit iodine organification, a process catalyzed by thyroid peroxidase. ATDs negatively impact the activity and numbers of intrathyroidal T cells, the aberrant thyrocyte expression of major histocompatibility complex class II, as well as the generation of reactive oxygen species, lipid peroxidation, and subsequent oxidative damage.

10Three compounds are available with methimazole (MMI) as the classical and most widely distributed ATD. In comparison, carbimazole (CBM) is an inactive drug and much less available worldwide. CBM is rapidly metabolized in the blood to MMI with an average 2-fold weaker potency than MMI. Propylthiouracil (PTU) is the least potent compound (10-fold weaker than MMI). However PTU additionally inhibits the thyroxine (T4) deiodination to 3,5,3′-triiodothyronine (T3) in peripheral tissues. MMI has the longest half-life, an acceptable and low side-effect profile and is, therefore, regarded as the standard ATD with the highest efficacy. Absorption of MMI following oral administration approximates 100% leading to peak serum levels within 1 to 2 hours. The intrathyroidal concentration of MMI is markedly higher than in the plasma with stable intrathyroidal levels for approximately 22 hours postresorption. Initial daily dosing of MMI depends on the severity of hyperthyroidism and is based on the elevation in free thyroid hormone levels; using 20 and 30 mg if fT4 is 2- and 3-fold increased, respectively. The inhibition of the T4 deiodination and the lower placental transfer and less severe PTU-caused embryopathy explain why PTU is the first-line therapy of both thyroid storm in GD as well as in the first 10 to 12 weeks of pregnancy.

11Overall, patients with newly diagnosed GD are offered 3 equally effective treatments; however, ATDs are by far the patient-preferred approach worldwide. An ATD, preferably MMI, is administered for 12 to 18 months according to the American and European guidelines. Discontinuation of ATD therapy is indicated after reaching both biochemical euthyroidism (thyroid-related hormones within the normal range) and serological conversion (negative TSH-R-Ab testing). Indeed, the measurement of TSH-R-Ab levels in general and stimulatory TSH-R-Abs in particular is clinically useful at 18 months and predictive of recurrence (persistent stimulatory TSH-R-Ab) or remission (negative TSH-R-Ab). The European guidelines recommend the continuation of a low-dose MMI administration for a further 12 months with repeated TSH-R-Ab testing after 1 year. Alternatively, definitive treatment with either RAI or TX may be considered (Fig. 1). The evidence-based titration regimen with MMI monotherapy is favored since the addition of levothyroxine to MMI (block and replace regimen) neither enhances the remission rate nor decreases the recurrence of hyperthyroidism. Only about 50% of patients receiving ATD for 12 to 18 months will achieve a permanent remission, namely biochemical euthyroidism and negative TSH-R-Abs. The magnitude and presence of serum TSH-R-Ab levels, but also goiter size, the severity of hyperthyroidism, nicotine, young age, and the postpartum period negatively impact the recurrence rate. Due to the low predictive value of each of the above risk factors, additional cumulative scores taking into account 4 baseline characteristics (TSH-R-Abs, fT4, goiter size, and age) have been proposed and were shown to provide suboptimal differentiation.

12The most common adverse events (AEs) ascribed to ATD include minor cutaneous allergic reactions, including rash (3-6%), pruritus (2-3%), and urticaria (1-2%), as well as dyspepsia (3-4%), nausea/gastric distress (2.4%), and arthralgia (1.6%). Cutaneous reactions to ATD occur early during therapy. Major AEs include agranulocytosis, hepatotoxicity, vasculitis, and discordant reports on pancreatitis. Agranulocytosis occurs in 0.2% to 0.5% of patients taking ATDs, foremost within 3 months after the start of therapy. The onset is abrupt with high fever and severe pharyngitis. Agranulocytosis is dose related with respect to MMI, but not with PTU. Instead of a previously presumed drug-induced toxic side-effect, agranulocytosis is apparently due to immune targeting of granulocytes with subsequent alterations of the cell membrane. Specific HLA alleles in Asians and Caucasians increase susceptibility to ATD-induced agranulocytosis. Management involves granulocyte colony-stimulating factor and antibiotics. PTU-induced vasculitis often occurs after years of treatment and is associated with perinuclear anticytoplasmic neutrophil antibodies. Hepatotoxicity occurs in 0.3% patients exposed to MMI and 0.15% of those given PTU, while MMI and PTU are associated with noninfectious hepatitis in 0.25% and 0.08% of cases, respectively, with higher rates of hepatic failure with PTU. Guidelines neither recommend monitoring of liver function and white blood cell count nor screening for anticytoplasmic neutrophil antibody positivity in patients on ATDs. However, timely and complete information of the patients pertaining to ATD-induced side-effects (pharyngitis, fever, jaundice, etc.) is warranted.

13Graves hyperthyroidism affects 0.1% to 0.2% of pregnancies and increases the risk of adverse outcomes in both mother and child. Optimally, hyperthyroid women should be rendered biochemically euthyroid prior to pregnancy. The managing physician is faced with challenges regarding indications and options for treatment, as well as use of ATDs. Both MMI and PTU cross the placenta with similar kinetics and may produce fetal–neonatal hypothyroidism and teratogenic effects in the embryo. The rates of ATD-induced birth anomalies are 3% to 4% and 2% to 3% for MMI (aplasia cutis, esophageal and choanal atresia) and PTU (branchial fistula, renal cysts), respectively. The critical time interval for exposure of the fetus is between week 5 to 6 and week 10.

14PTU is the guideline-recommended ATD during the first trimester of pregnancy; however, if the patient was on less than 10 mg of MMI prior to pregnancy and the serum free thyroid hormone levels are within the normal range, ATDs may be stopped at week 5 and serum free T4 and free T3 controlled weekly. When this risk is considered high (high TSH-R-Ab, GO present, MMI dose > 10 mg/day), the lowest possible dose of PTU should be administered (50-100 mg/day) while additional levothyroxine is discouraged. In the second and third trimesters, as well as during the postpartum period and lactation, PTU is replaced by MMI to reduce potential PTU-associated liver damage. Finally, TSH-R-Ab measurement is warranted in all female patients with a diagnosed autoimmune thyroid disease both prior to and during pregnancy, including those who previously had a definitive treatment (TX or RAI). The measurement of functional and specific (stimulatory or blocking) TSH-R-Abs via cell-based bioassays is clinically useful and predictive for a fetal and/or neonatal dysfunction, especially when serum TSH-R-Ab levels are higher than the 3-assay cut-off.

15If biochemical and/or serological (TSH-R-Ab positivity) hyperthyroidism persist 18 months after the start of MMI therapy, treatment with RAI or TX is usually considered. An adequate and safe alternative, which can be discussed and offered to all GD patients, is the unlimited continuation of low-dose MMI (Fig. 1). The same holds true for those who relapse after a previous first course of ATD. This is convincingly underlined by a recent prospective randomized clinical trial which showed a 4- to 5-fold increased cumulative incidence of hyperthyroidism recurrence in GD patients treated for an average of 19 months (±3 months) with MMI in contrast to a GD group treated for 95 months (±22 months, P <.001). Also, a low incidence of AEs is noted on a maintenance dose (2.5-5 mg/day) of MMI, with only 1.5% of patients experiencing severe AEs. Furthermore, numerous studies comparing long-term outcomes (2-11 years) in GD patients with continuous ATD administration or in those randomized to either ATD or RAI demonstrated stable euthyroidism and a paucity of ATD-induced AEs, lower management costs, and less frequent episodes of hypothyroidism in the ATD group. There was also a better remission rate of 63%, less weight gain, and less GO deterioration compared with RAI.

16Due to its significantly increased hepatotoxic risk in young subjects, PTU is not recommended in children and adolescents. As the remission rate is markedly lower than in adults, long-term (3-5 years) MMI is the mainstay of treatment in children with GD. In contrast, definitive treatment is preferred in older patients with thyrotoxicosis-induced cardiovascular complications. Alternatively, low-dose MMI is a satisfactory treatment for older individuals with mild GD.

17Cardiovascular morbidity and mortality have been associated with endogenous subclinical GD and completely suppressed serum TSH. The rate of progression of subclinical GD to overt hyperthyroidism was 30% in the subsequent 3 years, especially in those patients with persistent TSH-R-Ab. Therefore, treatment of subclinical GD is recommended in GD patients in general and in those >65 years, particularly in patients with completely suppressed serum TSH levels. ATDs are the first treatment of choice.

18Cardiac symptoms are frequently observed in patients with Graves hyperthyroidism, for example, sinus tachycardia, supraventricular arrhythmia, and atrial fibrillation in elderly people. Hence, beta-adrenergic blockade (eg, propranolol or bisoprolol) is indicated in the early stages of GD. High doses of propranolol (160-200 mg) inhibit both thyroid hormone releases from the thyroid as well as T4 deiodination in the periphery. Anticoagulation is indicated in older patients with supraventricular arrhythmia, especially in those >65 years with atrial fibrillation.

19RAI treatment is indicated in (1) patients with persistent hyperthyroidism after completion of a 12- to 18-month first course of ATD therapy, (2) those with a recurrence or relapse of thyrotoxicosis, (3) patients with poor compliance on ATDs, (4) subjects with major ATD-induced side-effects, and (5) individuals who choose this approach. Contraindications for RAI are (1) pregnancy and lactation, (2) GD with a nodular goiter and suspicion of thyroid cancer, (3) the presence of active GO, and (4) patients with an acknowledged high risk for the development and exacerbation of GO, for example, high stimulatory TSH-R-Ab, severe hyperthyroidism with high serum T3 levels, and smokers. Indeed RAI therapy exacerbates or induces de novo GO in 15% to 20% of GD patients via a marked increase of serum stimulatory TSH-R-Ab levels. Furthermore, severe deterioration of thyrotoxicosis and/or occurrence of the thyroid storm as an endocrine emergency have been observed after RAI. Hence, all candidates for a RAI treatment should be completely informed pertaining to the above described and acknowledged risks. The objective of the, in general, effective RAI therapy is to achieve biochemical hypothyroidism through a, frequently selected fixed, high dose of radionuclide and the subsequent destruction of the thyroid gland. Patients should be off ATDs 1 week prior to and after RAI administration as ATDs negatively impact the efficacy and success of RAI. Conception is allowed 6 months at the earliest after RAI for both sexes.

20Patients with differentiated thyroid cancer treated with RAI have a significantly increased risk of secondary malignancies. This was inconclusive for those treated with RAI for hyperthyroidism. However, recently a longitudinal study with a follow-up >25 years confirmed an increased risk of secondary cancers (breast, kidney, stomach) due to RAI treatment for hyperthyroidism. Mortality from breast (relative risk, RR 1.12) and solid cancers (RR 1.05) was significantly enhanced, while the association with solid cancer mortality increased with greater total administered RAI activity. In a further study of over 16 000 patients treated for hyperthyroidism, a trend towards a higher risk (HR 2.32) of non-Hodgkin’s Lymphoma in RAI-treated individuals was noted.

21Total TX is indicated in GD patients with (1) persistent hyperthyroidism and/or recurrence of thyrotoxicosis after the completion of a first course of ATD, (2) suspected thyroid cancer, (3) a large thyroid gland (>50-60 mL) and compressive symptoms, (4) nodular goiters and active GO, (5) concurrent hyperparathyroidism, and (6) pregnancy (second trimester). ATDs are required prior to TX especially in severe hyperthyroidism hence avoiding perioperative complications and uncontrolled thyroid dysfunction. Further, a solution containing potassium iodide given prior to TX decreases blood flow to the thyroid and intraoperative blood loss. Guidelines recommend that a high-volume surgeon markedly reduces the failure rate to below 1% making TX a cost-effective approach for GD. Potential adverse events of TX are laryngeal edema, recurrent laryngeal nerve injury, hypocalcemia, bleeding, and hypoparathyroidism (Table 1). The rate of the above complications remains low with experienced, high-volume surgeons and the risks of transient hypocalcemia and recurrent laryngeal nerve injury are <10% and <1%, respectively. Calcium substitution substantially lowers the risks of perioperative hypocalcemia. Finally, levothyroxine replacement is administered postoperatively based on a body mass index- or weight-adapted calculation.

22Thyroid dysfunction should be promptly restored as both hypothyroidism with elevated serum TSH as well hyperthyroidism negatively affect the clinical activity and severity of GO. TSH directly stimulates TSH-R expressing orbital target cells to release hydrophilic mucopolysaccharides and proinflammatory cytokines, while hyperthyroidism is associated with markedly increased serum levels of stimulatory TSH-R-Abs. Hence, both thyroid dysfunctions exacerbate the orbital inflammatory process with local edema, congestion, and resulting exophthalmos. Adequate levothyroxine (LT4) substitution or MMI administration are warranted to reach and maintain a stable euthyroid state. RAI should be avoided in all cases of active and/or moderate to severe GO and prophylactic glucocorticoids (GCs) are recommended in GD patients treated with RAI, especially in those at high risk for developing GO, for example, high stimulatory TSH-R-Ab and smokers. After confirmation of GO diagnosis, clinical disease activity, severity and presence of sight-threatening manifestations are assessed. Serum TSH-R-Ab levels in general and stimulatory TSH-R-Abs in particular are a reliable and highly sensitive biomarker of clinically active and severe GO.

23The current guidelines of the European Group on Graves’ Orbitopathy (EUGOGO) and of the European Thyroid Association recommend local treatment and selenium for mild GO, and high-dose intravenous glucocorticoid (IVGC) pulses as standard treatment of choice for active and moderate to severe disease, including optic neuropathy. The disease-modifying IVGC treatment of GO is not associated with secondary adrenocortical insufficiency. Prior treatment of orbital disease with IVGC markedly decreases the need for successive rehabilitative surgeries. Inflammatory symptoms and signs as well as clinical disease activity are sensitive to IVGC with response rates averaging 70% to 80%. To improve tolerability and decrease IVGC-induced morbidity, single (>0.75 g) and cumulative doses (>8 g) of methylprednisolone, and/or a consecutive-day regimen should be avoided. In comparison, clinical severity and the corresponding signs proptosis and diplopia respond less well to IVGCs. This is why retrobulbar radiotherapy is additionally indicated in patients with disturbances of eye muscle motility, while orbital decompression surgery is considered in subjects with persistent active and severe GO subsequent to immunosuppressive treatment. Hence, current guideline-recommended approaches may still require additional surgical corrections, due to partial or insufficient improvement of severity signs, in 20% to 30% of GO cases.

24The TSH-R is the primary target of orbital autoimmunity as convincingly demonstrated by animal models of GO, induced by immunization with TSH-R alone. Immunohistochemically analysis of human orbital tissue in GO reveals TSH-R immunoreactivity and TSH-R activation impacts orbital adipogenesis. However, recent in vitro experiments have shown that the IGF-1R is an additional key player and a relevant autoantigen in GO pathogenesis. This was first hypothesized by a British group, which demonstrated the displacement of the insulin-like factor-1 (IGF-1) by GD immunoglobulins from the binding sites of the IGF-1R on cultured fibroblasts surgically obtained from GO patients. This novel autoantigen is expressed on the surface of orbital target cells as well as on T and B cells in patients with GO. The TSH-R and the IGF-1R colocalize in thyrocytes and orbital fibroblasts, and IGF-1R-Abs have been observed in subjects with GD and/or GO. Subsequent to the binding of TSH-R-Abs to their ligand on TSH-R expressing cells, there is a “cross-talk” between the TSH-R and the IGF-1R leading to activation of IGF-1R-dependent downstream intracellular pathways.

25Further evidence of the major role of the IGF-1R in GO has been added by in vitro testing of the novel human anti-IGF-1R monoclonal antibody (mAb) teprotumumab. Binding of teprotumumab to its ligand was able to inhibit both activation of the IGF-1R and downstream intracellular signaling by the endogenous ligands, as well as induce internalization and degradation of the IGF-1R. In cultured fibroblasts, this mAb suppressed the IGF-1/TSH-R-Ab-stimulated release of chemokines. Further, teprotumumab reduced the TSH-stimulated release of proinflammatory cytokines from isolated fibrocytes of GD patients, and markedly decreased the expression of both TSH-R and IGF-1R in fibrocytes.

26Two large, consecutive, randomized, multicenter, placebo-controlled, phase II and III trials have demonstrated the efficacy and acceptable tolerability of teprotumumab in subjects with severe and active thyroid eye disease. This drug led to a rapid and impressive improvement of all symptoms and signs of disease severity and activity during and/or after the first cycle of 8 consecutive intravenous infusions over 24 weeks (primary endpoint). In both trials, significant increases in the total score of the disease-specific quality-of-life questionnaire were also observed at week 24. Early this year, teprotumumab was approved by the Food and Drug Administration for the treatment of adult patients with severe and active GO. However, to potentially implement this promising drug in the routine management of patients with inflammatory/severe GO as well as critically evaluate its exact role and place in the guideline-recommended treatment algorithm, additional data pertaining to durability of the short-term results and long-term safety and efficacy are keenly warranted. High costs, availability of the drug (currently commercially available in the USA only), and missing comparative trials with the current guideline-recommended standard regimen (IVGC) are additional issues of concern.

27Dermopathy and acropachy are very rare extrathyroidal manifestations of GD and occur in 1.5% to 2% and 0.3% to 0.5% of patients, respectively. Acropachy commonly manifests as clubbing of fingers and digits. The pathogenesis of both of extrathyroidal manifestations is similar to GO, and practically all patients with dermopathy and/or acropachy have also moderate to severe GO. Local steroid therapy and occlusive dressing might be helpful for dermopathy, while no specific treatment is available for acropachy.

28Poorly controlled hyperthyroidism increases the risk of COVID-19 infection, especially in elderly people. Uncontrolled thyrotoxicosis is associated with excess cardiovascular mortality. Infections, for example, COVID-19, may precipitate thyroid storm in patients with poorly controlled thyroid dysfunction. Thus, both COVID-19 infection and an unstable hyperthyroid state markedly increase morbidity and mortality risk in general, and in elderly people in particular. Hence, each patient with Graves hyperthyroidism should continue ATD medication and should be closely monitored by the managing physician. Further, patients with poorly controlled diabetes and/or adrenal insufficiency, and those on high-dose immunosuppressive GCs may be more susceptible to developing COVID-19 infection, as they are with any other infections. The morbidity associated with those conditions could increase susceptibility, as patients with adrenal failure are more prone to develop infections. Concomitant electrolyte imbalances are exacerbated by infection, causing dehydration, which can propagate an adrenal crisis and a potentially fatal cytokine storm. Hence, GO patients on GCs may have increased susceptibility to COVID-19 as a result of the immunosuppressive effects of GCs and potential adrenal failure. Prospective and randomized trials have shown that in contrast to oral GC therapy, IVGCs are not associated with secondary adrenal insufficiency. As the true impact of COVID-19 in immunosuppressed patients can neither be accurately evaluated nor predicted, a cautious approach is recommended for both patients who have recently finished the IVGC treatment, and especially for those who have completed a long-term course of oral GCs for GO. These subjects should be closely monitored if they become infected by COVID-19, as they are at risk of potentially developing acute adrenal failure. Is it worth mentioning that dexamethasone improves outcomes in severe COVID-19; however, unless sight-threatening forms are present, high-doses of GC and systemic treatment should be postponed, and local as well as preventive measures offered.

29Recent in vitro and in vivo research aims to introduce and establish new treatments for the management of Graves hyperthyroidism and its associated extrathyroidal manifestations. Both the TSH-R and the IGF-1R are the primary targets for these novel, but still exploratory, approaches. Other targets include either molecules relevant to the pathogenesis of GD/GO that play an important role within the immunological synapse and are expressed on the surface of B cells (eg, CD40 and CD20), or important proinflammatory cytokine receptors, for example, IL-6R (Fig. 2A and Fig. 2B) or tumor necrosis factor (TNF)α. In line with this, 2 TNFα blockers, etanercept and adalimumab, were tested with modest benefit. In contrast, far better results were observed with mycophenolate, an immunosuppressive drug with dual antiproliferative effects on T and B cells as well as on orbital target cells. Two randomized controlled trials encompassing more than 300 patients with active and severe GO demonstrated the safety and good tolerability of mycophenolate, as well as beneficial effects of the drug on eye symptoms and signs, clinical disease severity (proptosis, motility disturbances, and/or diplopia), and clinical activity (orbital inflammation). This clinical benefit was convincingly accompanied by a markedly improved disease-specific quality of life. Overall, the risk–benefit ratio of mycophenolate treatment in GO was highly favorable. Hence, mycophenolate is recommended as an efficacious, safe, and well-tolerated add-on drug to IVGCs in active/severe GO.

30However, the future causal treatment of GD/GO belongs to mAbs or small molecules that can inhibit activation/hypertrophy of thyrocytes and orbital target cells. In detail, the disease-specific and most effective way to inhibit the increased release of free thyroid hormones induced by GD is to administer a TSH-R antagonist able to block the TSH-R and the stimulatory effect of the TSH-R-Abs. In the United Kingdom, clinical trials testing the efficacy and safety of a monoclonal human antibody (K1-70) targeting and blocking TSH-R activation by stimulatory TSH-R-Abs are ongoing. Alternatively, small molecules which bind to the transmembrane domain of the TSH-R subsequently blocking its activation were recently introduced. A novel, selective TSH-R small-molecule antagonist (S37a) was reported to inhibit both TSH-R activation by TSH itself and activation by M22, a stimulating anti-TSH-R human mAb. Further, the clinical effect of a combination of different TSH-R peptides called ATX-GD-59, was assessed in untreated subjects with Graves hyperthyroidism. ATX-GD-59 is an “apitope,” restoring immune tolerance to the TSH-R. This “apitope” is able to both suppress the immune response against the TSH-R and generate suppressor, regulatory T cells. Seven of 10 treated GD patients showed a complete or partial response to ATX-GD-59.

31The CD40 molecule is abundantly expressed by thyrocytes and orbital target cells and CD40–CD154 interaction modulates humoral immunity within the immunological synapse. Iscalimab, an anti-CD40 mAb and a potent inhibitor of the CD40-CD40 ligand (CD154) costimulatory pathway, was administered to patients with untreated GD. Iscalimab was very well tolerated, with half of the subjects responding to the drug. In comparison, B cell targeting therapies include rituximab, an anti-CD20 humanized mAb causing B cell depletion, and an anti-BAFF mAb (belimumab) preventing BAFF from interacting with its receptors. Rituximab has been tested in GD leading to a decline of TSH-R-Abs. When administered to GO patients, grossly conflicting results were registered. High costs, low efficacy, and potential drug–related side effects (orbital edema and optic neuropathy) are major hurdles for the generalized use of rituximab in GO. Finally, when tested in an open-label study, a humanized recombinant IL6-R mAb (Tocilizumab) positively improved the clinical course of the disease and extraocular muscle motility in patients with steroid-resistant GO. However, a subsequent tocilizumab placebo-controlled randomized trial in GO patients only partially reproduced the earlier reported impressive findings.

32In conclusion, further controlled randomized studies are warranted to demonstrate the efficacy, safety, and clinical role of the above new compounds for GD and GO.